| RITECHEM PHARMACY LIMITED |
| Registered number: |
00639801 |
| Balance Sheet |
| as at 31 July 2025 |
|
| Notes |
|
|
2025 |
|
|
2024 |
| £ |
£ |
| Fixed assets |
| Tangible assets |
3 |
|
|
1,039 |
|
|
1,558 |
|
| Current assets |
| Debtors |
4 |
|
353,211 |
|
|
377,204 |
|
| Creditors: amounts falling due within one year |
5 |
|
(88,125) |
|
|
(95,160) |
|
| Net current assets |
|
|
|
265,086 |
|
|
282,044 |
|
| Total assets less current liabilities |
|
|
|
266,125 |
|
|
283,602 |
|
| Creditors: amounts falling due after more than one year |
6 |
|
|
(10,593) |
|
|
(21,480) |
|
|
|
| Net assets |
|
|
|
255,532 |
|
|
262,122 |
|
|
|
|
|
|
|
|
| Capital and reserves |
| Called up share capital |
|
|
|
25,371 |
|
|
25,371 |
| Revaluation Reserve |
7 |
|
|
6,481 |
|
|
6,481 |
| Profit and loss account |
|
|
|
223,680 |
|
|
230,270 |
|
| Shareholder's funds |
|
|
|
255,532 |
|
|
262,122 |
|
|
|
|
|
|
|
|
| The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The member has not required the company to obtain an audit in accordance with section 476 of the Act. |
| The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
| Dr Sam Hedayati |
| Director |
| Approved by the board on 20 November 2025 |
|
| RITECHEM PHARMACY LIMITED |
| Notes to the Accounts |
| for the year ended 31 July 2025 |
|
|
| 1 |
Accounting policies |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Tangible fixed assets |
|
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: |
|
|
Fixtures, fittings, tools and equipment |
over 5 years |
|
|
Debtors |
|
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts. |
|
|
Creditors |
|
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. |
|
|
Borrowings |
|
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. |
|
|
Share capital |
|
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. |
|
|
|
|
|
|
| 2 |
Employees |
2025 |
|
2024 |
| Number |
Number |
|
|
Average number of persons employed by the company |
1 |
|
1 |
|
|
|
|
|
|
|
|
|
|
| 3 |
Tangible fixed assets |
|
|
|
|
|
|
|
|
Plant and machinery etc |
| £ |
|
Cost |
|
At 1 August 2024 |
2,597 |
|
At 31 July 2025 |
2,597 |
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
At 1 August 2024 |
1,039 |
|
Charge for the year |
519 |
|
At 31 July 2025 |
1,558 |
|
|
|
|
|
|
|
|
|
|
Net book value |
|
At 31 July 2025 |
1,039 |
|
At 31 July 2024 |
1,558 |
|
|
| 4 |
Debtors |
2025 |
|
2024 |
| £ |
£ |
|
|
Other debtors |
353,211 |
|
377,204 |
|
|
|
|
|
|
|
|
|
|
| 5 |
Creditors: amounts falling due within one year |
2025 |
|
2024 |
| £ |
£ |
|
|
Trade creditors |
180 |
|
180 |
|
Taxation and social security costs |
2,300 |
|
2,300 |
|
Other creditors |
85,645 |
|
92,680 |
|
|
|
|
|
|
88,125 |
|
95,160 |
|
|
|
|
|
|
|
|
|
|
| 6 |
Creditors: amounts falling due after one year |
2025 |
|
2024 |
| £ |
£ |
|
|
Bank loans |
10,593 |
|
21,480 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7 |
Revaluation reserve |
2025 |
|
2024 |
| £ |
£ |
|
|
At 1 August 2024 |
6,481 |
|
6,481 |
|
|
At 31 July 2025 |
6,481 |
|
6,481 |
|
|
|
|
|
|
|
|
|
|
| 8 |
Other information |
|
|
RITECHEM PHARMACY LIMITED is a private company limited by shares and incorporated in England. Its registered office is: |
|
277-279 Chiswick High Road |
|
London |
|
W4 4PU |